Back to News
Market Impact: 0.25
JNJ Announces CHMP's Recommendation For Approval Of TECVAYLI
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Johnson & Johnson announced that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended an indication extension for TECVAYLI to treat adult patients with relapsed/refractory multiple myeloma. The positive regulatory recommendation could expand TECVAYLI's eligible patient population in Europe, although final European Commission approval is still pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
JNJ0.55
More News
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- India forces caller-ID apps to feed spam reports to telcos
- Analysis-Russia sanctions bill gives Trump sweeping new tariff powers
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal